← 홈

Antibody · 폐암 (NSCLC)

4개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4개
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodyAHotEli Lilly-linkersPhase 2

EGFR inhibitor (Cetuximab, Cetuximab (EGFR inhibitor))

Advanced Solid Tumor; NSCLC · EGFR

#EGFR#Antibody#Phase2#인기#항체+5
효능 ORR 70.6%임상시험 166상태 ACTIVE
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE